Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells
about
Exciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaErbB receptors: from oncogenes to targeted cancer therapiesCross talk of tyrosine kinases with the DNA damage signaling pathwaysStructural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs)HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature reviewMolecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.The RAS signal transduction pathway and its role in radiation sensitivity.c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft modelsRadiation-induced Akt activation modulates radioresistance in human glioblastoma cells.Reversion of the ErbB malignant phenotype and the DNA damage response.Enhancing radiation therapy for patients with glioblastoma.RNA aptamers and their therapeutic and diagnostic applications.Disabling receptor ensembles with rationally designed interface peptidomimetics.Identification of molecular subtypes of glioblastoma by gene expression profiling.EGFRvIII-mediated radioresistance through a strong cytoprotective response.Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.
P2860
Q24632791-7BABF837-26C4-4506-80D1-DDFA9033A8E3Q24683709-FAC7F41F-EE1F-4C3D-ADF5-B5713F2FCE8BQ26778614-ECC15369-92C2-412D-AA7A-85F703A45EBEQ27670462-C1F39292-BB45-4094-A9DE-9CCADCEB1A11Q28144746-ED3A5197-A949-46E6-8722-E42C909E6AC7Q30932448-8EA22991-7AAD-46F2-A13C-97E44961FA88Q33644407-E8C6CB50-B999-4FAF-822F-7151709386BDQ34225928-8D3D30FE-C674-4D9F-BAED-0C032D167882Q34332525-ED331635-1E46-41C0-8BCF-E0E909D37277Q34722457-37D7931B-4D10-4351-9A18-DD4D771C4002Q35208824-5954EDED-19A5-454D-856A-780CD8176EDEQ35218681-18671EF8-BBCE-4F98-A3C2-25E061D875F0Q36523502-0831093E-2189-408E-B886-E54C7741BE6AQ37237126-D1CDCC37-F641-451E-A9EF-42AC8D09741AQ37395564-09BB40FA-82C8-4F6C-854E-836F640CE55AQ38047648-5B640EF8-8B84-4ABB-8245-4F1AD7EF691DQ38101608-B0DB4CEA-38AB-4E90-92DC-95F4345D8C5DQ39862703-E32281E0-4634-4543-B840-1979413EDBB5Q43993786-6E72E57E-84CF-4101-A45C-B453638320BFQ48332534-4CEA58FE-5F11-4633-8055-6A2F46E0A4E8Q50335608-CE9C5E09-5EB9-4840-85B1-BE78B5A14F7CQ55476205-CE0A4EF6-2704-4972-B5AC-86DED6DF4B12
P2860
Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Conversion of a radioresistant ...... ignaling in human cancer cells
@ast
Conversion of a radioresistant ...... ignaling in human cancer cells
@en
Conversion of a radioresistant ...... gnaling in human cancer cells.
@nl
type
label
Conversion of a radioresistant ...... ignaling in human cancer cells
@ast
Conversion of a radioresistant ...... ignaling in human cancer cells
@en
Conversion of a radioresistant ...... gnaling in human cancer cells.
@nl
prefLabel
Conversion of a radioresistant ...... ignaling in human cancer cells
@ast
Conversion of a radioresistant ...... ignaling in human cancer cells
@en
Conversion of a radioresistant ...... gnaling in human cancer cells.
@nl
P2093
P2860
P356
P1476
Conversion of a radioresistant ...... ignaling in human cancer cells
@en
P2093
P2860
P304
10842-10847
P356
10.1073/PNAS.95.18.10842
P407
P577
1998-09-01T00:00:00Z